MicroRNA 141 Expression Is a Potential Prognostic Marker of Biliary Tract Cancers
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: In recent years, a large number of microribonucleic acids (miRNAs) have been identified as putative prognostic biomarkers for solid cancers because of their role in controlling the expression of oncogenes and tumor suppressor genes. The aim of this study was to verify the utility of miRNA 141 as a prognostic biomarker of biliary tract cancers. Methods: From June 2010 to June 2012, common bile duct cancer tissue samples and matched noncancerous tissues from the ampulla of Vater were obtained from patients with biliary tract cancer undergoing endoscopic retrograde cholangiopancreatography. Using quantitative real-time polymerase chain reaction assays, we measured the mean relative expression levels of miRNA 141 in both groups of tissues. Overexpression of miRNA 141 was defined as a greater than 2-fold increase in expression levels as determined by the 2-ΔΔCt method. Results: In a cohort of 38 patients with biliary tract cancers (seven gallbladder, 13 hilar, and 18 distal bile duct cancers), 26 patients (68.4%) were male, and the median age was 69.5 (52 to 85) years. Nineteen patients (50%) had undergone R0 resection procedures, including three Whipple operations, seven pylorus-preserving pancreaticoduodenectomies, six bile duct resections, and three extended lobectomies. Among the patients who had undergone R0 resection, the overexpression of miRNA 141 was significantly associated with shorter disease-free survival and a greater risk of angiolymphatic invasion. Among the patients who did not undergo R0 resection, miRNA 141 overexpression was significantly associated with reduced overall survival. Conclusions: Overexpression of miRNA 141 is an indicator of a poor prognosis in patients with biliary tract cancer, suggesting that miRNA 141 may be a valuable prognostic biomarker of this disease.
Abstract
Background/Aims: In recent years, a large number of microribonucleic acids (miRNAs) have been identified as putative prognostic biomarkers for solid cancers because of their role in controlling the expression of oncogenes and tumor suppressor genes. The aim of this study was to verify the utility of miRNA 141 as a prognostic biomarker of biliary tract cancers. Methods: From June 2010 to June 2012, common bile duct cancer tissue samples and matched noncancerous tissues from the ampulla of Vater were obtained from patients with biliary tract cancer undergoing endoscopic retrograde cholangiopancreatography. Using quantitative real-time polymerase chain reaction assays, we measured the mean relative expression levels of miRNA 141 in both groups of tissues. Overexpression of miRNA 141 was defined as a greater than 2-fold increase in expression levels as determined by the 2-ΔΔCt method. Results: In a cohort of 38 patients with biliary tract cancers (seven gallbladder, 13 hilar, and 18 distal bile duct cancers), 26 patients (68.4%) were male, and the median age was 69.5 (52 to 85) years. Nineteen patients (50%) had undergone R0 resection procedures, including three Whipple operations, seven pylorus-preserving pancreaticoduodenectomies, six bile duct resections, and three extended lobectomies. Among the patients who had undergone R0 resection, the overexpression of miRNA 141 was significantly associated with shorter disease-free survival and a greater risk of angiolymphatic invasion. Among the patients who did not undergo R0 resection, miRNA 141 overexpression was significantly associated with reduced overall survival. Conclusions: Overexpression of miRNA 141 is an indicator of a poor prognosis in patients with biliary tract cancer, suggesting that miRNA 141 may be a valuable prognostic biomarker of this disease.
참고문헌 (15)
- "Cancer information services" (2016)[URL]
- Grunnet M, "Serum tumor markers in bile duct cancer: a review", Biomarkers, 19, pp.437~443 (2014)
- Croce CM, "Causes and consequences of microRNA dysregulation in cancer", Nat Rev Genet, 10, pp.704~714 (2009)
- Halkova T, "MicroRNAs in pancreatic cancer: involvement in carcinogenesis and potential use for diagnosis and prognosis", Gastroenterol Res Pract, 2015, pp.892903~ (2015)
- Sakai NS, "A review of the current understanding and clinical utility of miRNAs in esophageal cancer", Semin Cancer Biol, 23(6 Pt B), pp.512~521 (2013)
- Lyra-González I, "MicroRNAs dysregulation in hepatocellular carcinoma: insights in genomic medicine", World J Hepatol, 7, pp.1530~1540 (2015)
- Meng F, "Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines", Gastroenterology, 130, pp.2113~2129 (2006)
- Schmittgen TD, "A high-throughput method to monitor the expression of microRNA precursors", Nucleic Acids Res, 32, pp.e43~ (2004)
- Blechacz B, "Clinical diagnosis and staging of cholangiocarcinoma", Nat Rev Gastroenterol Hepatol, 8, pp.512~522 (2011)
- Zhang J, "MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin", Gastroenterology, 143, pp.246~256 (2012)
- Meng F, "Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes", Oncogene, 27, pp.378~386 (2008)
- Mott JL, "mir-29 regulates Mcl-1protein expression and apoptosis", Oncogene, 26, pp.6133~6140 (2007)
- Peng F, "Direct targeting of SUZ12", ROCK2 by miR-200b, Br J Cancer, pp.2013, 109[DOI]
- Knijn N, "Histopathological evaluation of resected colorectal cancer liver metastases:what should be done?", Histopathology, 63, pp.149~156 (2013)
- Wu CF, "Prognostic value of metastatic N1lymph node ratio and angiolymphatic invasion in patients with pathologic stage IIA non-small cell lung cancer", Medicine, 93, pp.e102~ (2014)